Panfil AR - Search Results

1

An HTLV-1 envelope mRNA vaccine is immunogenic and protective in New Zealand rabbits.

Tu JJ, King E, Maksimova V, Smith S, Macias R, Cheng X, Vegesna T, Yu L, Ratner L, Green PL, Niewiesk S, Richner JM, Panfil AR. Tu JJ, et al. Among authors: panfil ar. J Virol. 2024 Feb 20;98(2):e0162323. doi: 10.1128/jvi.01623-23. Epub 2024 Jan 9. J Virol. 2024. PMID: 38193692

2

Animal Models Utilized in HTLV-1 Research.

Panfil AR, Al-Saleem JJ, Green PL. Panfil AR, et al. Virology (Auckl). 2013 Nov 18;4:49-59. doi: 10.4137/VRT.S12140. eCollection 2013. Virology (Auckl). 2013. PMID: 25512694 Free PMC article. Review.

3

Human T-cell leukemia virus-associated malignancy.

Panfil AR, Martinez MP, Ratner L, Green PL. Panfil AR, et al. Curr Opin Virol. 2016 Oct;20:40-46. doi: 10.1016/j.coviro.2016.08.009. Epub 2016 Aug 31. Curr Opin Virol. 2016. PMID: 27591679 Free PMC article. Review.

4

HTLV-1 CTCF-binding site is dispensable for in vitro immortalization and persistent infection in vivo.

Martinez MP, Cheng X, Joseph A, Al-Saleem J, Panfil AR, Palettas M, Dirksen WP, Ratner L, Green PL. Martinez MP, et al. Among authors: panfil ar. Retrovirology. 2019 Dec 21;16(1):44. doi: 10.1186/s12977-019-0507-9. Retrovirology. 2019. PMID: 31864373 Free PMC article.

5

CRISPR Genome Editing Applied to the Pathogenic Retrovirus HTLV-1.

Panfil AR, Green PL, Yoder KE. Panfil AR, et al. Front Cell Infect Microbiol. 2020 Dec 23;10:580371. doi: 10.3389/fcimb.2020.580371. eCollection 2020. Front Cell Infect Microbiol. 2020. PMID: 33425776 Free PMC article. Review.

6

Human T-Cell Leukemia Virus Type 1 Envelope Protein: Post-Entry Roles in Viral Pathogenesis.

Maksimova V, Panfil AR. Maksimova V, et al. Among authors: panfil ar. Viruses. 2022 Jan 13;14(1):138. doi: 10.3390/v14010138. Viruses. 2022. PMID: 35062342 Free PMC article. Review.

7

The Past, Present, and Future of a Human T-Cell Leukemia Virus Type 1 Vaccine.

Tu JJ, Maksimova V, Ratner L, Panfil AR. Tu JJ, et al. Among authors: panfil ar. Front Microbiol. 2022 May 4;13:897346. doi: 10.3389/fmicb.2022.897346. eCollection 2022. Front Microbiol. 2022. PMID: 35602078 Free PMC article. Review.

8

HTLV-1 intragenic viral enhancer influences immortalization phenotype in vitro, but is dispensable for persistence and disease development in animal models.

Maksimova V, Smith S, Seth J, Phelps C, Niewiesk S, Satou Y, Green PL, Panfil AR. Maksimova V, et al. Among authors: panfil ar. Front Immunol. 2022 Jul 25;13:954077. doi: 10.3389/fimmu.2022.954077. eCollection 2022. Front Immunol. 2022. PMID: 35958554 Free PMC article.

9

The PRMT5 inhibitor EPZ015666 is effective against HTLV-1-transformed T-cell lines in vitro and in vivo.

Ernzen K, Melvin C, Yu L, Phelps C, Niewiesk S, Green PL, Panfil AR. Ernzen K, et al. Among authors: panfil ar. Front Microbiol. 2023 Feb 2;14:1101544. doi: 10.3389/fmicb.2023.1101544. eCollection 2023. Front Microbiol. 2023. PMID: 36819050 Free PMC article.

10

HTLV-1 Hbz protein, but not hbz mRNA secondary structure, is critical for viral persistence and disease development.

Maksimova V, Wilkie T, Smith S, Phelps C, Melvin C, Yu L, Niewiesk S, Green PL, Panfil AR. Maksimova V, et al. Among authors: panfil ar. PLoS Pathog. 2023 Jun 16;19(6):e1011459. doi: 10.1371/journal.ppat.1011459. eCollection 2023 Jun. PLoS Pathog. 2023. PMID: 37327244 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

28 results

Search Page